Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;GXYxMUUN3ME2wMlAxODJ6NzFOwG0> NIXkNG9USU6JRWK=
LC-2-ad M2nnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LHSGlEPTB;MD6wNFA{OTdizszN Mn6wV2FPT0WU
RL95-2 NXmw[os{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zJR2lEPTB;MD6wNFA3PjhizszN MVXTRW5ITVJ?
MZ1-PC NUT2e|ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXpTpl3UUN3ME2wMlAxODd{OTFOwG0> MYLTRW5ITVJ?
TE-8 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMECxNVch|ryP MX7TRW5ITVJ?
SW954 NHLINIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37oS2lEPTB;MD6wNFEyQSEQvF2= NYKxRY5nW0GQR1XS
TE-11 NFLDW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD2TWM2OD1yLkCwNVI{KM7:TR?= NX60WHE5W0GQR1XS
PSN1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[0U5BKSzVyPUCuNFAyOyEQvF2= Mn:yV2FPT0WU
MOLT-4 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMECxOFkh|ryP MmfqV2FPT0WU
697 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMECxOUDPxE1? NGDjbo5USU6JRWK=
ETK-1 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXITZFKSzVyPUCuNFAyPTJizszN NXLUNIl4W0GQR1XS
TE-10 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMECxOVQh|ryP M2HFS3NCVkeHUh?=
HUTU-80 NF:5S5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHKe4JKUUN3ME2wMlAxOTZ6IN88US=> MUPTRW5ITVJ?
NTERA-S-cl-D1 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnqTWM2OD1yLkCwNlA6KM7:TR?= NUizNVZEW0GQR1XS
MFH-ino NFLOOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMECyOlgh|ryP NGHCZlRUSU6JRWK=
IA-LM MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPHTWM2OD1yLkCwNlgh|ryP NIXxcJFUSU6JRWK=
MC116 NGiyflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fuVmlEPTB;MD6wNFI5QSEQvF2= M3jFVHNCVkeHUh?=
RKO MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnqXW9KSzVyPUCuNFAzQThizszN MX\TRW5ITVJ?
MRK-nu-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMECyPVkh|ryP NEL2UlJUSU6JRWK=
VA-ES-BJ MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ewNGlEPTB;MD6wNFMh|ryP MVXTRW5ITVJ?
KALS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K1fGlEPTB;MD6wNFMxQCEQvF2= MoDCV2FPT0WU
BB30-HNC NXjCUm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvKTWM2OD1yLkCwN|E1KM7:TR?= NXnHOHAxW0GQR1XS
ACN MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMECzNVYh|ryP MkTDV2FPT0WU
TE-9 NXe0eVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMECzNlYh|ryP M2Dp[HNCVkeHUh?=
SIG-M5 NWHCZlRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\GcGlEPTB;MD6wNFMzPyEQvF2= M1PMS3NCVkeHUh?=
no-10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMECzOlIh|ryP MUnTRW5ITVJ?
EW-1 M{P0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonyTWM2OD1yLkCwN|cyKM7:TR?= NXu1Z29oW0GQR1XS
SK-LMS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33iWmlEPTB;MD6wNFQxOSEQvF2= MWXTRW5ITVJ?
GT3TKB MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPEdXNsUUN3ME2wMlAxPDN2IN88US=> NGO3[GFUSU6JRWK=
ES4 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEC0OFkh|ryP M1nMTnNCVkeHUh?=
IMR-5 NXf2c4JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEC0OUDPxE1? MkXkV2FPT0WU
NCI-H1648 NX;iT3l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r0d2lEPTB;MD6wNFQ3QSEQvF2= NETsdJdUSU6JRWK=
MV-4-11 NYTWd5dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDYTWM2OD1yLkCwOFc2KM7:TR?= NHTl[3BUSU6JRWK=
SK-UT-1 MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3vTFFTUUN3ME2wMlAxPDhizszN NWDuZ2R2W0GQR1XS
NB13 NEixSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHVUpNKSzVyPUCuNFA1QTFizszN NInNd5pUSU6JRWK=
DJM-1 M1racmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfRdollUUN3ME2wMlAxPTNizszN MkjKV2FPT0WU
ES8 M{\rN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMEC1N|gh|ryP MnXJV2FPT0WU
TE-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvDVnVqUUN3ME2wMlAxPTdizszN MmXuV2FPT0WU
KS-1 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHnTWM2OD1yLkCwOVgzKM7:TR?= MX\TRW5ITVJ?
TE-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPPc3pSUUN3ME2wMlAxPjB4IN88US=> Mni2V2FPT0WU
ATN-1 NV65T5BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHixdGFKSzVyPUCuNFA3ODlizszN NGHYTnhUSU6JRWK=
A4-Fuk NYTCUW9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHrcYhqUUN3ME2wMlAxPjFzIN88US=> MVjTRW5ITVJ?
ALL-PO MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPZSpR4UUN3ME2wMlAxPjNizszN MX;TRW5ITVJ?
BE-13 M{Ttd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13afWlEPTB;MD6wNFY{PiEQvF2= M1f0eHNCVkeHUh?=
KM12 NEPLOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TISGlEPTB;MD6wNFY{PyEQvF2= Mor2V2FPT0WU
NOS-1 M171UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfWcHZKSzVyPUCuNFA3PSEQvF2= NUTyWnBLW0GQR1XS
SW962 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGzSJFKUUN3ME2wMlAxPjZ{IN88US=> M3HMUnNCVkeHUh?=
OCUB-M M1:wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3jTWM2OD1yLkCwOlYzKM7:TR?= MnzlV2FPT0WU
NCI-H510A MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnMXYpjUUN3ME2wMlAxPjZ3IN88US=> M3[xNnNCVkeHUh?=
EW-16 M{\PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEC2PVQh|ryP M4GyXHNCVkeHUh?=
KGN MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DtVGlEPTB;MD6wNFcyOiEQvF2= M2niVXNCVkeHUh?=
LS-411N M4\EeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXaTWM2OD1yLkCwO|E4KM7:TR?= MnT6V2FPT0WU
Becker M4W5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n1dmlEPTB;MD6wNFczKM7:TR?= MmHTV2FPT0WU
HC-1 M3vC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\OSGlEPTB;MD6wNFczOSEQvF2= MWrTRW5ITVJ?
CESS NES2RVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnzTWM2OD1yLkCwO|M4KM7:TR?= NYDMbHpWW0GQR1XS
KURAMOCHI NYXKb4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PSUWlEPTB;MD6wNFc1QCEQvF2= NHfKfnpUSU6JRWK=
TGBC24TKB MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3wTWM2OD1yLkCwO|UzKM7:TR?= NY\mfmdnW0GQR1XS
SW982 NXjqclFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMEC3OlYh|ryP NWewTIhQW0GQR1XS
HCE-4 M4PadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\EPJRKSzVyPUCuNFA4PjdizszN MofEV2FPT0WU
LOUCY MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEC3O|Uh|ryP NXu4WZdVW0GQR1XS
8-MG-BA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nj[GlEPTB;MD6wNFc6PiEQvF2= MlrwV2FPT0WU
HT-144 M1K5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEC4JO69VQ>? MXTTRW5ITVJ?
LXF-289 NWPrZ4trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\jTW45UUN3ME2wMlAxQDF6IN88US=> NVXpb3VHW0GQR1XS
RS4-11 NWrqe5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXBTmJKSzVyPUCuNFA5OzZizszN NYjJU|ZrW0GQR1XS
DEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESwdYFKSzVyPUCuNFA5PDVizszN NV\pc2hwW0GQR1XS
OCI-AML2 NHexS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37VUGlEPTB;MD6wNFg2OiEQvF2= NYXV[XBlW0GQR1XS
CCRF-CEM NGTJdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEC4O|Eh|ryP MoqyV2FPT0WU
A388 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrlOGJKSzVyPUCuNFA5PzRizszN NHfEN|JUSU6JRWK=
KNS-42 NUiydoRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEC4PVEh|ryP M4T5bHNCVkeHUh?=
OVCAR-4 NX7YWZoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSzfnZSUUN3ME2wMlAxQTB2IN88US=> NYnyVYgzW0GQR1XS
NCI-H1355 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEC5NVQh|ryP M4HMb3NCVkeHUh?=
BL-70 NWS0b5F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPvTWM2OD1yLkCwPVMh|ryP MX;TRW5ITVJ?
BL-41 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLRUlhlUUN3ME2wMlAxQTN2IN88US=> MlXqV2FPT0WU
A101D MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWyTWM2OD1yLkCwPVYh|ryP NXrDU5dkW0GQR1XS
HL-60 NUHPdG1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInRSW5KSzVyPUCuNFA6PjZizszN MmO0V2FPT0WU
COR-L279 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn35TWM2OD1yLkCwPVk6KM7:TR?= Ml:4V2FPT0WU
NCI-SNU-16 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfWOpVKSzVyPUCuNFExODhizszN MYPTRW5ITVJ?
Calu-6 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEGwNVIh|ryP NVrlTIJuW0GQR1XS
SR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfGVVVKSzVyPUCuNFExOjZizszN NWTBc3gzW0GQR1XS
QIMR-WIL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzYT4JKSzVyPUCuNFExOzNizszN MWLTRW5ITVJ?
LB647-SCLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzkTWM2OD1yLkCxNFUyKM7:TR?= M2TpW3NCVkeHUh?=
RPMI-8226 NFrub2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXyN|hKSzVyPUCuNFEyODJizszN M1rNfXNCVkeHUh?=
SK-PN-DW NGfielBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzZWpFKSzVyPUCuNFEyOTJizszN NEGwXotUSU6JRWK=
SF268 NEe4bXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjKNIxKSzVyPUCuNFEyPTFizszN M4iz[3NCVkeHUh?=
HD-MY-Z NGrjZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL0eoh7UUN3ME2wMlAyOTZ|IN88US=> Mn71V2FPT0WU
DOHH-2 NInzdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX74[JN[UUN3ME2wMlAyOjB|IN88US=> M13D[3NCVkeHUh?=
SCC-3 NVXOXpJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEGyNFQh|ryP Ml\WV2FPT0WU
ST486 NFLtW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LFe2lEPTB;MD6wNVIxPCEQvF2= M3vMN3NCVkeHUh?=
NALM-6 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrrWZJKSzVyPUCuNFEzOTRizszN NYLpeIc5W0GQR1XS
NCI-H1436 M2H2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXvTWM2OD1yLkCxNlMyKM7:TR?= NIXxVm5USU6JRWK=
KE-37 NVPpUGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\1TWM2OD1yLkCxNlM1KM7:TR?= NI\Ub3ZUSU6JRWK=
RPMI-8402 NIPnPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEGyOVYh|ryP NFrtTWxUSU6JRWK=
RXF393 M2fVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fYWWlEPTB;MD6wNVI2PyEQvF2= NXvMdFR3W0GQR1XS
KARPAS-45 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEGyO{DPxE1? NHfBZotUSU6JRWK=
HOP-62 NXfIcWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELqfmhKSzVyPUCuNFEzPzZizszN MkHYV2FPT0WU
ES1 NGDKbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CwWWlEPTB;MD6wNVI5QCEQvF2= NWX5fGtzW0GQR1XS
L-363 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfXe|RKUUN3ME2wMlAyOzVzIN88US=> Mki2V2FPT0WU
GI-1 NIDMd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GyRWlEPTB;MD6wNVM4OyEQvF2= MYHTRW5ITVJ?
CTV-1 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3CdZVnUUN3ME2wMlAyPDd6IN88US=> MnXwV2FPT0WU
TE-5 NEnRWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HhXWlEPTB;MD6wNVQ6PiEQvF2= NULIXJdoW0GQR1XS
SNU-C2B MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LSNWlEPTB;MD6wNVQ6PiEQvF2= NV\kb3pnW0GQR1XS
K-562 NHzi[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrEcotGUUN3ME2wMlAyPTF4IN88US=> MnPMV2FPT0WU
SNB75 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEG1OEDPxE1? NVK2dFBFW0GQR1XS
MOLT-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVeyfnI1UUN3ME2wMlAyPjN5IN88US=> NHjQXWlUSU6JRWK=
LS-123 NHLIVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHjR5JCUUN3ME2wMlAyPjZ2IN88US=> NGn4T|JUSU6JRWK=
NCI-SNU-5 NXvHSJM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPsTWM2OD1yLkCxO|AyKM7:TR?= MlPYV2FPT0WU
Daudi MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnsNZVDUUN3ME2wMlAyPzB6IN88US=> MlrPV2FPT0WU
A253 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[yVIpiUUN3ME2wMlAyPzN6IN88US=> NXHNdIVsW0GQR1XS
TGBC1TKB MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LkOGlEPTB;MD6wNVc2OiEQvF2= NFXyO4hUSU6JRWK=
SJSA-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjYeY8yUUN3ME2wMlAyPzZ5IN88US=> M{XjOHNCVkeHUh?=
NCCIT NF;yRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm4TWM2OD1yLkCxO|Y6KM7:TR?= MXfTRW5ITVJ?
NCI-H69 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEG3O|gh|ryP NYfy[oVVW0GQR1XS
SH-4 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzkenNnUUN3ME2wMlAyQDl3IN88US=> MmPXV2FPT0WU
HCC1187 NIHl[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fx[WlEPTB;MD6wNVkzPCEQvF2= MWHTRW5ITVJ?
HCC1599 M4Do[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEKwNkDPxE1? NXrSR481W0GQR1XS
ONS-76 NXvxOpliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEKwN|Yh|ryP MmnrV2FPT0WU
KU812 NV;zdYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzXTWM2OD1yLkCyNFM6KM7:TR?= NFPSO5FUSU6JRWK=
ML-2 M3T0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LwOGlEPTB;MD6wNlA1PyEQvF2= MkC5V2FPT0WU
HCE-T NF[xboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HZXGlEPTB;MD6wNlA6OiEQvF2= NHTWWYlUSU6JRWK=
NCI-H446 M2jWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDUbGZQUUN3ME2wMlAzOTF{IN88US=> M{XW[nNCVkeHUh?=
RPMI-6666 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEKxOFkh|ryP M3\VVnNCVkeHUh?=
MOLT-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEKxOVMh|ryP MYLTRW5ITVJ?
JiyoyeP-2003 MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMEKxO|Yh|ryP NFjNUHFUSU6JRWK=
MHH-PREB-1 M3fzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMEKxPVEh|ryP M4jFUXNCVkeHUh?=
MC-CAR NYWwWnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\BTWM2OD1yLkCyN|I3KM7:TR?= MnW5V2FPT0WU
BC-3 NGnQcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXJTWM2OD1yLkCyN|Q1KM7:TR?= MoLYV2FPT0WU
KINGS-1 MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37GSWlEPTB;MD6wNlM2PSEQvF2= NE\ncYpUSU6JRWK=
PF-382 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\CXWlEPTB;MD6wNlM4QCEQvF2= NEKzW4VUSU6JRWK=
J-RT3-T3-5 M2XIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEKzPFMh|ryP M1PtR3NCVkeHUh?=
SF539 NX3yW5RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEK0NFEh|ryP NWrF[lBPW0GQR1XS
LB831-BLC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\KNWlEPTB;MD6wNlQ5PSEQvF2= MV\TRW5ITVJ?
DMS-114 M1jZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfHN4hKSzVyPUCuNFI2ODJizszN NWfuXIZOW0GQR1XS
LB1047-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7QTWM2OD1yLkCyOVEh|ryP NWq3U5hXW0GQR1XS
LB771-HNC M{jPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPOTWM2OD1yLkCyOVM1KM7:TR?= NU\TbG5oW0GQR1XS
BB65-RCC Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjJOm9IUUN3ME2wMlAzPTN2IN88US=> NGfnNmZUSU6JRWK=
BV-173 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfDTWM2OD1yLkCyOVU1KM7:TR?= NVzWW2FHW0GQR1XS
ARH-77 NYrFXGE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEK2NFEh|ryP M37OVHNCVkeHUh?=
IST-MEL1 MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnPb2xbUUN3ME2wMlAzPjJ|IN88US=> M33hcnNCVkeHUh?=
NB1 M2\zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEK2PFch|ryP MV\TRW5ITVJ?
EoL-1-cell M1nuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEK2PFgh|ryP MXTTRW5ITVJ?
KY821 M2juXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPxTWM2OD1yLkCyOlk4KM7:TR?= MV\TRW5ITVJ?
CMK NGi4TJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\kXnpNUUN3ME2wMlAzPzN2IN88US=> NWDLUmpTW0GQR1XS
NCI-H2126 NEXN[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;HTWM2OD1yLkCyO|Y5KM7:TR?= M1vu[HNCVkeHUh?=
NCI-H526 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf6fmdKSzVyPUCuNFI5QTFizszN MmrhV2FPT0WU
COLO-684 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH61PYFKSzVyPUCuNFI6ODhizszN M3PwfHNCVkeHUh?=
NCI-H747 NFjJ[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zheWlEPTB;MD6wNlk{OyEQvF2= MUjTRW5ITVJ?
JAR M{nsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXKOpZvUUN3ME2wMlAzQTR4IN88US=> MVvTRW5ITVJ?
MEG-01 M2PSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yTVVCUUN3ME2wMlAzQTd6IN88US=> M4nEeXNCVkeHUh?=
MONO-MAC-6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nsTmlEPTB;MD6wN|AzOyEQvF2= NFSwPHpUSU6JRWK=
IST-SL1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;KOHBKSzVyPUCuNFMxPDJizszN NXPWPZdJW0GQR1XS
CPC-N MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XFNmlEPTB;MD6wN|A4QSEQvF2= NFi5[|hUSU6JRWK=
NCI-H1963 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMEOxN|Eh|ryP NXzBbohGW0GQR1XS
K052 M2PTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrqdlh5UUN3ME2wMlA{OjR5IN88US=> Mlj2V2FPT0WU
KM-H2 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KzTWlEPTB;MD6wN|MxPyEQvF2= MVzTRW5ITVJ?
TE-12 M1Xnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEOzNFkh|ryP M{[0OHNCVkeHUh?=
TK10 NXfnVploT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHQNXA5UUN3ME2wMlA{OzV4IN88US=> NEHuNZlUSU6JRWK=
NMC-G1 M4ryfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK1WJNmUUN3ME2wMlA{PDV{IN88US=> NV;Oc25{W0GQR1XS
no-11 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIraPGtKSzVyPUCuNFM1PzhizszN MlfzV2FPT0WU
NCI-H524 NFTKZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrzOnNKSzVyPUCuNFM2OjlizszN M3rybHNCVkeHUh?=
MHH-CALL-2 Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDBUWZKSzVyPUCuNFM2PjJizszN M3nPSHNCVkeHUh?=
GB-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfMSlJvUUN3ME2wMlA{PiEQvF2= NW\3SHNGW0GQR1XS
OPM-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf4bodKSzVyPUCuNFM3PzNizszN MnzHV2FPT0WU
RH-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6wNnZHUUN3ME2wMlA{QDF7IN88US=> NHT6TXlUSU6JRWK=
NCI-H64 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17YRWlEPTB;MD6wN|g2PyEQvF2= MYPTRW5ITVJ?
EVSA-T NFn0WJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEO5NlMh|ryP NHvJdGVUSU6JRWK=
KARPAS-299 NW\QS25WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEO5PEDPxE1? NUfWRVVKW0GQR1XS
MZ7-mel MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W5NGlEPTB;MD6wOFA1KM7:TR?= MX\TRW5ITVJ?
LB373-MEL-D MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMESxNFUh|ryP NIWyTm5USU6JRWK=
HEL NFHCXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[yS2lEPTB;MD6wOFE1KM7:TR?= NYryNW5FW0GQR1XS
SW872 NYjVTIFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XNeGlEPTB;MD6wOFIyKM7:TR?= M{\aXnNCVkeHUh?=
DU-4475 M3XtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXUZZlJUUN3ME2wMlA1OjR2IN88US=> MlrlV2FPT0WU
IST-SL2 NF3rNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fKXmlEPTB;MD6wOFI4PSEQvF2= NHfEPW5USU6JRWK=
NCI-H82 M{TsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LWdGlEPTB;MD6wOFMxPyEQvF2= MXnTRW5ITVJ?
LC4-1 M130TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3JcXZkUUN3ME2wMlA1OzVzIN88US=> NUP3bmxOW0GQR1XS
HDLM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMESzPVIh|ryP MYrTRW5ITVJ?
MMAC-SF NV:4XIhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3vfFB4UUN3ME2wMlA1PTN2IN88US=> NGDGVGZUSU6JRWK=
L-540 M{S0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHqTWM2OD1yLkC0OlM6KM7:TR?= Mnv2V2FPT0WU
MZ2-MEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XSb2lEPTB;MD6wOFc1OiEQvF2= NELTU5NUSU6JRWK=
LU-134-A MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\ldJBTUUN3ME2wMlA1Pzd|IN88US=> NVTOXYF4W0GQR1XS
UACC-257 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\yPWlEPTB;MD6wOFg1QSEQvF2= M3HZNXNCVkeHUh?=
NCI-H1581 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WzTWlEPTB;MD6wOFk2OyEQvF2= MUjTRW5ITVJ?
NB17 M3rNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjhRVJKSzVyPUCuNFQ6PzlizszN MXzTRW5ITVJ?
SBC-1 MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf2TWM2OD1yLkC1NFQzKM7:TR?= MorGV2FPT0WU
TALL-1 NUPaVlJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vHd2lEPTB;MD6wOVA1PSEQvF2= MWDTRW5ITVJ?
NCI-H1304 NXnBWJptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Pjd2lEPTB;MD6wOVIxQCEQvF2= NV3hSlYxW0GQR1XS
NEC8 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j6ZWlEPTB;MD6wOVI5PiEQvF2= NEjRXVNUSU6JRWK=
CAL-148 M3KwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfoSW9KSzVyPUCuNFU1OzlizszN M4\N[nNCVkeHUh?=
CGTH-W-1 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSzTWM2OD1yLkC1OFQ6KM7:TR?= M3Pmc3NCVkeHUh?=
NCI-H889 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\PRmlEPTB;MD6wOVU6OiEQvF2= MV3TRW5ITVJ?
GR-ST Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEW2NlEh|ryP NXnWR2c4W0GQR1XS
KARPAS-422 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[1fG5KSzVyPUCuNFU3PSEQvF2= NVH6[GVzW0GQR1XS
RPMI-8866 M{C4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEW3NVIh|ryP NH3CSZVUSU6JRWK=
SCLC-21H M4DGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nje2lEPTB;MD6wOVg5PCEQvF2= M1XKWnNCVkeHUh?=
COR-L88 M2THd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe4U3d1UUN3ME2wMlA2QTJ5IN88US=> NIDKfFNUSU6JRWK=
LU-139 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LKVGlEPTB;MD6wOVk5PiEQvF2= NEOzNnpUSU6JRWK=
SF126 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\sTWM2OD1yLkC2NVM{KM7:TR?= NEHYZ3pUSU6JRWK=
NCI-H1882 NGHYdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX61PXZqUUN3ME2wMlA3PDJ2IN88US=> NXnUfWNSW0GQR1XS
EW-24 NFHaUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPCOGNKSzVyPUCuNFY1QDNizszN M2izVnNCVkeHUh?=
CP67-MEL NHrsd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwME[4NUDPxE1? MWrTRW5ITVJ?
DG-75 NFSwOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfNTWM2OD1yLkC2PFk6KM7:TR?= MXzTRW5ITVJ?
LOXIMVI NFPOWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj5TWM2OD1yLkC3NFI5KM7:TR?= M3;DOXNCVkeHUh?=
HH NVvVZVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXoTWM2OD1yLkC3NVU4KM7:TR?= MmnMV2FPT0WU
K5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe2WG1TUUN3ME2wMlA4OjJ4IN88US=> NIjNVlVUSU6JRWK=
EC-GI-10 M3fIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMEeyOVch|ryP MkH2V2FPT0WU
SK-N-DZ MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHtZoJmUUN3ME2wMlA4OzB5IN88US=> MlTDV2FPT0WU
A3-KAW NH2wXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT2U|NKSzVyPUCuNFc{PTFizszN NEXtfVJUSU6JRWK=
MLMA Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D1SGlEPTB;MD6wO|Q3PSEQvF2= NX\SU5NVW0GQR1XS
LB996-RCC NFvzPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfSTWM2OD1yLkC3O|A4KM7:TR?= MoqyV2FPT0WU
OS-RC-2 NUfKO|dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfHcJpyUUN3ME2wMlA4PzR6IN88US=> NYTuTXNCW0GQR1XS
CTB-1 NE\zV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[4fYV5UUN3ME2wMlA4QDFizszN NXLL[3pmW0GQR1XS
IST-MES1 NH;1UnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HYeGlEPTB;MD6wO|kyOiEQvF2= NIXnc2JUSU6JRWK=
LS-1034 NYjqWHR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\QWGQzUUN3ME2wMlA5ODN3IN88US=> NGnUbZVUSU6JRWK=
HT MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEiwPFYh|ryP M3rUdHNCVkeHUh?=
NCI-H2141 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHq[YNKSzVyPUCuNFgyKM7:TR?= MXvTRW5ITVJ?
LB2518-MEL NWW3PGV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6xTlhKSzVyPUCuNFgyPDFizszN NYnNVm9GW0GQR1XS
GI-ME-N MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLaW|hKSzVyPUCuNFg1PTJizszN M2XP[nNCVkeHUh?=
TGW M3rnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOzOnRKSzVyPUCuNFg3ODdizszN NGW4cHZUSU6JRWK=
SK-NEP-1 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;pV3hKSzVyPUCuNFg3PDFizszN MV\TRW5ITVJ?
NOMO-1 NYT5R|FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL3TZRjUUN3ME2wMlA6Ojd3IN88US=> NV36eZV7W0GQR1XS
ES6 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPuVYZYUUN3ME2wMlA6PTh7IN88US=> NVThc41jW0GQR1XS
NCI-H209 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHrXnZKSzVyPUCuNFk4QDZizszN MoDkV2FPT0WU
GAK M3PDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHPTWM2OD1yLkGwNVYh|ryP MX7TRW5ITVJ?
BC-1 MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXsTWM2OD1yLkGwN|YyKM7:TR?= NFTPPJZUSU6JRWK=
KLE MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDEWJF3UUN3ME2wMlExPDR|IN88US=> NUXMXFVrW0GQR1XS
EW-3 NWLlVFJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMUC5PEDPxE1? NELINWpUSU6JRWK=
NKM-1 NIHDbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fkOmlEPTB;MD6xNVEh|ryP M3jtdnNCVkeHUh?=
D-336MG NGW3SlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMUGyOFQh|ryP M3noRnNCVkeHUh?=
NB69 M1jRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16wRWlEPTB;MD6xNVMxOSEQvF2= Ml7mV2FPT0WU
D-263MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHWdIlKSzVyPUCuNVE4OTJizszN M4eycnNCVkeHUh?=
KP-N-YS M3XC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nwemlEPTB;MD6xNlI6OSEQvF2= MlXhV2FPT0WU
NCI-H1155 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jlRWlEPTB;MD6xNlU2QCEQvF2= NITYNmlUSU6JRWK=
BOKU M{TqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\2fY5KSzVyPUCuNVI2PzlizszN MoGyV2FPT0WU
LAMA-84 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHiTWM2OD1yLkGyPVkh|ryP NIfBVWlUSU6JRWK=
Raji NFf2THRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPXZVJjUUN3ME2wMlE{OTF5IN88US=> M3f3eXNCVkeHUh?=
LU-65 NHHuZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMUOzNFch|ryP NHjnVY9USU6JRWK=
NCI-H187 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjQe5pKSzVyPUCuNVM6OjRizszN NYm5VYZ7W0GQR1XS
GCIY NXjYfFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTWR3Z4UUN3ME2wMlE1QTBzIN88US=> NV;Zcm1wW0GQR1XS
NCI-H2107 MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO3TWM2OD1yLkG1NFgh|ryP NVjnSWg6W0GQR1XS
NCI-H1522 NUO3dZVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX5R45KSzVyPUCuNVUzPjZizszN MVLTRW5ITVJ?
NB6 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS1dXd3UUN3ME2wMlE2PjJ|IN88US=> M{nOdnNCVkeHUh?=
EM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH4RWVbUUN3ME2wMlE2PzB4IN88US=> NUO1fW5sW0GQR1XS
HCC2218 M4i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMUW5PEDPxE1? MojCV2FPT0WU
NCI-H748 M2\kOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;STWM2OD1yLkG2N|c3KM7:TR?= MUHTRW5ITVJ?
MS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIezOYVKSzVyPUCuNVY2OzdizszN Mlu0V2FPT0WU
NB5 NY\yXWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjoTWM2OD1yLkG2OVk4KM7:TR?= M4nJRXNCVkeHUh?=
OMC-1 NIj6PHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTpSGJNUUN3ME2wMlE3Pjh6IN88US=> NHjZZoJUSU6JRWK=
NCI-H345 NV;Td3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHiTWM2OD1yLkG2PVI5KM7:TR?= MoGzV2FPT0WU
L-428 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\jc2lEPTB;MD6xOlk1PSEQvF2= NWTPfYRuW0GQR1XS
SCH NVjWfXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT5dohFUUN3ME2wMlE5Pjh3IN88US=> NGjFUFJUSU6JRWK=
NCI-H1417 NH;SSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLFdnZKSzVyPUCuNVkzOjdizszN MnKwV2FPT0WU
COLO-320-HSR MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jF[WlEPTB;MD6xPVU{OiEQvF2= MnWwV2FPT0WU
BT-474 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnMb3VKSzVyPUCuNlA5QTJizszN NHr2em9USU6JRWK=
GDM-1 NITycHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMkG5O|Eh|ryP MVzTRW5ITVJ?
NCI-H2196 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnUe5RJUUN3ME2wMlIzOjN3IN88US=> MoG5V2FPT0WU
KP-N-RT-BM-1 NHX5XoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnsOFlKSzVyPUCuNlI{PDlizszN NFjkSlVUSU6JRWK=
KNS-81-FD M4f4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7PTWM2OD1yLkKyPVU5KM7:TR?= NYfTbmFFW0GQR1XS
COLO-668 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMkO2O|Uh|ryP M1vleHNCVkeHUh?=
C2BBe1 NIXo[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrZc4JKSzVyPUCuNlY4PDdizszN NXG5dod[W0GQR1XS
Ramos-2G6-4C10 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33nVmlEPTB;MD6yOlk2PCEQvF2= NW[2dIM{W0GQR1XS
CAS-1 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjCTWM2OD1yLkK3NFk3KM7:TR?= MUfTRW5ITVJ?
GOTO MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7GWodKSzVyPUCuNlc5QTRizszN NGK3UnRUSU6JRWK=
LP-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMkiwOVch|ryP NVnpSJlUW0GQR1XS
NCI-SNU-1 M3[yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LifGlEPTB;MD6yPVQzOiEQvF2= MYfTRW5ITVJ?
EB-3 M4\wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMkm5O|kh|ryP NXLuVJc4W0GQR1XS
MHH-NB-11 NF;KeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q5WGlEPTB;MD6zNFQxOiEQvF2= MX\TRW5ITVJ?
SK-N-FI NFzHeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;2WHc6UUN3ME2wMlMyPjl{IN88US=> MYLTRW5ITVJ?
HCC2157 NWDyUW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13hUWlEPTB;MD6zN|kyOyEQvF2= NVP5d5hqW0GQR1XS
SIMA MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnt[3BKSzVyPUCuN|Q2QDFizszN Mki5V2FPT0WU
MDA-MB-134-VI MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;HV2lEPTB;MD6zOlkzQCEQvF2= MnPNV2FPT0WU
NCI-H1694 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j2ZmlEPTB;MD6zO{DPxE1? MX7TRW5ITVJ?
EHEB NVn3dY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwM{mwPFUh|ryP NUnFUmV3W0GQR1XS
U-266 NFPtR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfzfJlxUUN3ME2wMlM6QDR4IN88US=> M2rLUHNCVkeHUh?=
LC-1F M{TmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDRTWM2OD1yLkSzO|Y2KM7:TR?= NHr4cpZUSU6JRWK=
SHP-77 NITJTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HJdmlEPTB;MD60O|g2PSEQvF2= NHLGV4VUSU6JRWK=
LS-513 NEPBVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjmZnRMUUN3ME2wMlQ6OzB5IN88US=> MXLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 2年-20℃
6月-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
エタノール 18 mg/mL (21.07 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

カスタマーフィードバック (2)


Click to enlarge
Rating
Source , , ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck
Method Confocal Laser Scanning Microscopy Study
Cell Lines HeLa cells
Concentrations 5 μM
Incubation Time 24 h
Results From the figure, it was clear that interestingly α-TOS-Paclitaxel-NP induced highest PARP expression compared to α-TOS-CDDP-NP and α-TOS-Dox-NP.

Click to enlarge
Rating
Source RSC Adv , 2011, 1, 884-892. Paclitaxel purchased from Selleck
Method Microscope image
Cell Lines U937 cells
Concentrations
Incubation Time 24 h
Results The ODS-treated cells in Fig. b looked identical to the untreated cells in Fig. a with a similar rate of natural cell death of less than 3%. When Taxol microcrystals are added to the cell culture (the standard way that Taxol is released into biological systems), decreased cell proliferation rate, pronounced swelling and vacuolization are observed, as shown in Fig. c.

文献中の引用 (14)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ